<DOC>
	<DOCNO>NCT00225719</DOCNO>
	<brief_summary>Currently available therapy treat Acute Coronary Syndromes ( ACS ) several limitation include ; relatively long treatment duration require apparent significant benefit ; inability achieve reversal atherosclerotic process ; poor patient compliance due chronicity therapy . This study assess effect rHDL compare placebo index atherosclerosis progression regression assess intravascular ultrasound ( IVUS ) patient acute coronary syndrome ( ACS ) .</brief_summary>
	<brief_title>Effect rHDL Atherosclerosis - Safety Efficacy : THE ERASE TRIAL</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Male female 30 75 year age Recent acute coronary syndrome , define unstable angina , nonQ wave myocardial infarction , ST elevation indicative myocardial infarction , within last 14 day &gt; 50 % stenosis visual angiographic estimation leave main artery Renal insufficiency Severe liver disease Congestive heart failure define NYHA classification functional Class III Class IV Previous plan coronary artery bypass surgery</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>